Asociación Europea para el Estudio de la Diabetes (EASD) 2025 (Parte 1)

URL canonica: https://calculadoras.nmn.mx/infografias/asociacion-europea-estudio-diabetes-easd-2025-parte-1

Tipo: INFOGRAFIA

Areas terapeuticas

  • Cardiometabolico

Padecimientos

  • Diabetes

Contenido

Referencia de MedPoint.

Referencias

  1. Eriksen, L.B., Stidsen, J.V., Olesen, T.B., Nielsen J.S., Olsen, M.H., Højlund, K., Domazet, S.L. (2025). Association between self-reported physical activity and cardiovascular events and all-cause mortality in individuals recently diagnosed with type 2 diabetes. Diabetologia, 68 (Suppl. 1): S5. https://doi.org/10.1007/s00125-025-06497-1
  2. Kristoffersen, S.F., Domazet, S., Pouwer, F., Nielsen, J., Olesen, T., Stidsen, J., Olsen, M.H., Højlund, K. (2025). Physical activity and health-related quality of life: a bidirectional association in individuals recently diagnosed with type 2 diabetes. Diabetologia, 68 (Suppl. 1): S66. https://doi.org/10.1007/s00125-025-06497-1
  3. Schechter, M., Mosenzon, O., Cohen, Y., Fishkin, A., Leibowitz, G., Aharon-Hananel, G. (2025). Mortality, kidney and safety outcomes with SGLT2 inhibitors vs DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids. Diabetologia, 68 (Suppl. 1): S107. https://doi.org/10.1007/s00125-025-06497-1
  4. Dinsdale, M.M., Cardoso, P., McGovern, A.P., Hattersley, A.T., Jones, A.G., McKinley, T.J., Shields, B.M., Young, K.G., Dennis, J.M. (2025). Impact of increased SGLT2 inhibitor initiation on HbA1c, weight, and diabetes complications across age and frailty subgroups in the UK, 2019-2024. Diabetologia, 68 (Suppl. 1): S107-S108. https://doi.org/10.1007/s00125-025-06497-1
  5. Gottfried, J., Gajewska, K., Hever, A., Hernández, B., Lloyd, C., Nouwen, A., O’Donnell, S., Rodrigues, R., Schmitz, N., & Deschênes, S. (2025). Diabetes and depressive symptoms: Examining the potential roles of country-level and individual-level factors across European countries.Diabetologia, 68 (Suppl. 1): S203. https://doi.org/10.1007/s00125-025-06497-1
  6. Gugliandolo S., Morciano C., Leccisotti L., Capece U., A. Guarneri A., Mezza T., Di Giuseppe G., Ciccarelli G., Soldovieri L., Brunetti M., Avolio A., Splendore A., Calcagni M., Giaccari A. , Cinti F. (2025). A short term treatment with an SGLT-2i is associated with a reduction in insulin-stimulated renal glucose uptake. Diabetologia, 68 (Suppl. 1): S110. https://doi.org/10.1007/s00125-025-06497-1